Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 449

1.

Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology.

Droz JP, Aapro M, Balducci L, Boyle H, Van den Broeck T, Cathcart P, Dickinson L, Efstathiou E, Emberton M, Fitzpatrick JM, Heidenreich A, Hughes S, Joniau S, Kattan M, Mottet N, Oudard S, Payne H, Saad F, Sugihara T.

Lancet Oncol. 2014 Aug;15(9):e404-14. doi: 10.1016/S1470-2045(14)70018-X. Review.

PMID:
25079103
2.

Actinomycin D, cisplatin, and etoposide regimen is associated with almost universal cure in patients with high-risk gestational trophoblastic neoplasia.

Even C, Pautier P, Duvillard P, Floquet A, Kerbrat P, Troalen F, Rey A, Balleyguier C, Tazi Y, Leary A, Augereau P, Morice P, Droz JP, Fizazi K, Lhommé C.

Eur J Cancer. 2014 Aug;50(12):2082-9. doi: 10.1016/j.ejca.2014.05.002. Epub 2014 Jun 5.

PMID:
24910417
3.

Randomized phase II study of nintedanib in metastatic castration-resistant prostate cancer postdocetaxel.

Droz JP, Medioni J, Chevreau C, De Mont-Serrat H, Merger M, Stopfer P, Kaiser R, Oudard S.

Anticancer Drugs. 2014 Oct;25(9):1081-8. doi: 10.1097/CAD.0000000000000131.

PMID:
24849708
4.

Occupational exposures in rare cancers: A critical review of the literature.

Charbotel B, Fervers B, Droz JP.

Crit Rev Oncol Hematol. 2014 May;90(2):99-134. doi: 10.1016/j.critrevonc.2013.12.004. Epub 2013 Dec 14. Review.

5.

[Treatment of testicular cancer].

Droz JP, Boyle H, Culine S, Fizazi K, Fléchon A, Massard C.

Bull Cancer. 2013 Dec;100(12):1319-32. doi: 10.1684/bdc.2013.1863. Review. French.

PMID:
24316884
6.

Risk-adapted, dose escalation study of weekly docetaxel in the first-line treatment of elderly patients with advanced cancer.

Culine S, Terret C, Cupissol D, Romieu G, Fabbro M, Pouessel D, Droz JP, Gourgou S.

J Geriatr Oncol. 2013 Apr;4(2):122-7. doi: 10.1016/j.jgo.2012.11.002. Epub 2012 Dec 14.

PMID:
24071537
7.

Sorafenib and sunitinib for elderly patients with renal cell carcinoma.

Derbel Miled O, Dionne C, Terret C, Segura-Ferlay C, Flechon A, Neidhart EM, Negrier S, Droz JP.

J Geriatr Oncol. 2013 Jul;4(3):255-61. doi: 10.1016/j.jgo.2013.04.004. Epub 2013 May 9.

PMID:
24070463
8.

Management of brain metastases from germ cell tumors: a single center experience.

Boyle HJ, Jouanneau E, Droz JP, Fléchon A.

Oncology. 2013;85(1):21-6. doi: 10.1159/000351812. Epub 2013 Jun 29.

PMID:
23816811
9.

[Primary mucinous carcinoma of the eyelid. Case report].

Diwo E, Merle H, Gérard M, Couppié P, Lamarche F, Droz JP.

J Fr Ophtalmol. 2013 May;36(5):e83-6. doi: 10.1016/j.jfo.2012.08.010. Epub 2013 Apr 22. French.

10.

Tumor marker kinetics predict outcome in patients with relapsed disseminated non-seminomatous germ-cell tumors.

Massard C, Kramar A, Beyer J, Hartmann JT, Lorch A, Pico JL, Rosti G, Droz JP, Fizazi K.

Ann Oncol. 2013 Feb;24(2):322-8. doi: 10.1093/annonc/mds504. Epub 2012 Oct 26.

11.

Sarcoid-like granulomatosis and testicular germ cell tumor: the 'Great Imitator'.

Kaikani W, Boyle H, Chatte G, de la Roche E, Errihani H, Droz JP, Fléchon A.

Oncology. 2011;81(5-6):319-24. doi: 10.1159/000334239. Epub 2011 Dec 15.

PMID:
22179558
12.

Retroperitoneal vascular surgery for the treatment of giant growing teratoma syndrome.

Stella M, Gandini A, Meeus P, Aleksic I, Flechon A, Cropet C, Droz JP, Rivoire M.

Urology. 2012 Feb;79(2):365-70. doi: 10.1016/j.urology.2011.08.076. Epub 2011 Dec 14.

PMID:
22173179
13.

Results of combined treatment of anaplastic thyroid carcinoma (ATC).

Derbel O, Limem S, Ségura-Ferlay C, Lifante JC, Carrie C, Peix JL, Borson-Chazot F, Bournaud C, Droz JP, de la Fouchardière C.

BMC Cancer. 2011 Nov 1;11:469. doi: 10.1186/1471-2407-11-469.

14.

[High dose chemotherapy and germ cell tumor].

Massard C, Fléchon A, Fizazi K, Droz JP.

Bull Cancer. 2011 Aug;98(8):945-9. doi: 10.1684/bdc.2011.1406. Review. French.

PMID:
21821481
15.

Treatment of uncommon malignant tumours of the bladder.

Boyle H, Fléchon A, Droz JP.

Curr Opin Urol. 2011 Sep;21(5):309-14. doi: 10.1097/MOU.0b013e3283495758. Review.

PMID:
21814051
16.

[The role of chemotherapy in the management of bladder cancer].

Ismaili N, Amzerin M, Elmajjaoui S, Droz JP, Flechon A, Errihani H.

Prog Urol. 2011 Jun;21(6):369-82. doi: 10.1016/j.purol.2011.02.005. Epub 2011 Mar 29. Review. French.

PMID:
21620296
17.

Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial.

Fléchon A, Pouessel D, Ferlay C, Perol D, Beuzeboc P, Gravis G, Joly F, Oudard S, Deplanque G, Zanetta S, Fargeot P, Priou F, Droz JP, Culine S.

Ann Oncol. 2011 Nov;22(11):2476-81. doi: 10.1093/annonc/mdr004. Epub 2011 Mar 24.

18.

Targeted therapies and thyroid cancer: an update.

de la Fouchardiere C, Droz JP.

Anticancer Drugs. 2011 Aug;22(7):688-99. doi: 10.1097/CAD.0b013e32834319c7. Review.

PMID:
21200314
19.

[Rare tumours: a new heading in Bulletin du cancer].

Massard C, Droz JP.

Bull Cancer. 2010 Sep;97(9):1031-9. doi: 10.1684/bdc.2010.1171. French.

PMID:
20813656
20.

Potential drug interactions in elderly cancer patients.

Girre V, Arkoub H, Puts MT, Vantelon C, Blanchard F, Droz JP, Mignot L.

Crit Rev Oncol Hematol. 2011 Jun;78(3):220-6. doi: 10.1016/j.critrevonc.2010.05.004. Epub 2010 Jul 1. Review.

PMID:
20594867
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk